CN111712499A - 一种atr抑制剂及其应用 - Google Patents

一种atr抑制剂及其应用 Download PDF

Info

Publication number
CN111712499A
CN111712499A CN201980012249.5A CN201980012249A CN111712499A CN 111712499 A CN111712499 A CN 111712499A CN 201980012249 A CN201980012249 A CN 201980012249A CN 111712499 A CN111712499 A CN 111712499A
Authority
CN
China
Prior art keywords
compound
synthesis
esi
solution
give
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980012249.5A
Other languages
English (en)
Other versions
CN111712499B (zh
Inventor
钱文远
王剑
李婕
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wuxi Zhikang Hongyi Biotechnology Co ltd
Original Assignee
Shijiazhuang Sagacity New Drug Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shijiazhuang Sagacity New Drug Development Co Ltd filed Critical Shijiazhuang Sagacity New Drug Development Co Ltd
Publication of CN111712499A publication Critical patent/CN111712499A/zh
Application granted granted Critical
Publication of CN111712499B publication Critical patent/CN111712499B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

本发明公开了作为ATR抑制剂的一类化合物，以及在制备作为ATR抑制剂的药物中的应用。具体公开了式(Ⅰ)所示化合物、其异构体或其药学上可接受的盐。

Description

PCT国内申请，说明书已公开。

Claims (16)

  1. PCT国内申请，权利要求书已公开。
CN201980012249.5A 2018-02-07 2019-02-02 一种atr抑制剂及其应用 Active CN111712499B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201810124494 2018-02-07
CN2018101244942 2018-02-07
CN2018113615125 2018-11-15
CN201811361512 2018-11-15
PCT/CN2019/074578 WO2019154365A1 (zh) 2018-02-07 2019-02-02 一种atr抑制剂及其应用

Publications (2)

Publication Number Publication Date
CN111712499A true CN111712499A (zh) 2020-09-25
CN111712499B CN111712499B (zh) 2023-06-02

Family

ID=67548753

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980012249.5A Active CN111712499B (zh) 2018-02-07 2019-02-02 一种atr抑制剂及其应用

Country Status (18)

Country Link
US (1) US11434232B2 (zh)
EP (1) EP3753937B1 (zh)
JP (1) JP7290651B2 (zh)
CN (1) CN111712499B (zh)
AU (1) AU2019217388C1 (zh)
BR (1) BR112020016020A8 (zh)
CA (1) CA3090330A1 (zh)
DK (1) DK3753937T3 (zh)
FI (1) FI3753937T3 (zh)
HR (1) HRP20240161T1 (zh)
IL (1) IL276489B1 (zh)
LT (1) LT3753937T (zh)
PL (1) PL3753937T3 (zh)
PT (1) PT3753937T (zh)
RS (1) RS65147B1 (zh)
SG (1) SG11202007485PA (zh)
SI (1) SI3753937T1 (zh)
WO (1) WO2019154365A1 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3967694A4 (en) * 2019-06-06 2022-12-07 Beijing Tide Pharmaceutical Co., Ltd. TRI-SUBSTITUTED PYRIMIDINE COMPOUND IN POSITIONS 2, 4, 6 USED AS ATR KINASE INHIBITOR
AU2020325416A1 (en) * 2019-08-06 2022-02-03 Wuxi Biocity Biopharmaceutics Co., Ltd. Crystalline form of ATR inhibitor and use thereof
CN115551860A (zh) * 2020-05-20 2022-12-30 北京泰德制药股份有限公司 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物
US20230212165A1 (en) * 2020-05-29 2023-07-06 Shenzhen Lingfang Biotech Co., Ltd. Fluoropyrrolopyridine compound and application thereof
IL299368A (en) * 2020-06-24 2023-02-01 Astrazeneca Uk Ltd A combination of an antibody-drug conjugate and an ATR inhibitor
KR20230035070A (ko) * 2020-07-03 2023-03-10 안텐진 디스커버리 리미티드 Atr 억제제 및 이의 용도
CN116178366A (zh) * 2021-11-26 2023-05-30 深圳市瓴方生物医药科技有限公司 氟代吡啶并吡咯类化合物的晶型及其制备方法
WO2023131234A1 (en) * 2022-01-06 2023-07-13 Shanghai Antengene Corporation Limited Crystalline forms of an atr inhibitor
WO2023215133A1 (en) * 2022-05-02 2023-11-09 AcuraStem Incorporated Pikfyve kinase inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009093981A1 (en) * 2008-01-23 2009-07-30 S Bio Pte Ltd Triazine compounds as kinase inhibitors
CN103068391A (zh) * 2010-06-11 2013-04-24 阿斯利康(瑞典)有限公司 吗啉代嘧啶及其治疗用途
CN111655688A (zh) * 2017-09-08 2020-09-11 蓝谷制药有限责任公司 经取代的吡咯并吡啶类化合物作为atr抑制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
UY32351A (es) * 2008-12-22 2010-07-30 Astrazeneca Ab Compuestos de pirimidinil indol para uso como inhibidores de atr
US9481670B2 (en) 2011-01-25 2016-11-01 Sphaera Pharma Pte. Ltd. Triazine compounds
AR095443A1 (es) * 2013-03-15 2015-10-14 Fundación Centro Nac De Investig Oncológicas Carlos Iii Heterociclos condensados con acción sobre atr
TWI656121B (zh) * 2014-08-04 2019-04-11 德商拜耳製藥公司 ２－（嗎啉－４－基）－１，７－萘啶

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009093981A1 (en) * 2008-01-23 2009-07-30 S Bio Pte Ltd Triazine compounds as kinase inhibitors
CN103068391A (zh) * 2010-06-11 2013-04-24 阿斯利康(瑞典)有限公司 吗啉代嘧啶及其治疗用途
CN111655688A (zh) * 2017-09-08 2020-09-11 蓝谷制药有限责任公司 经取代的吡咯并吡啶类化合物作为atr抑制剂

Also Published As

Publication number Publication date
JP7290651B2 (ja) 2023-06-13
FI3753937T3 (fi) 2024-01-31
IL276489A (en) 2020-09-30
EP3753937B1 (en) 2024-01-10
PT3753937T (pt) 2024-02-06
LT3753937T (lt) 2024-02-26
JP2021512908A (ja) 2021-05-20
SI3753937T1 (sl) 2024-03-29
EP3753937A4 (en) 2021-07-07
AU2019217388A1 (en) 2020-09-03
RU2020128324A (ru) 2022-03-09
IL276489B1 (en) 2024-05-01
CA3090330A1 (en) 2019-08-15
WO2019154365A1 (zh) 2019-08-15
BR112020016020A2 (pt) 2020-12-08
RS65147B1 (sr) 2024-02-29
BR112020016020A8 (pt) 2023-04-25
PL3753937T3 (pl) 2024-04-02
SG11202007485PA (en) 2020-09-29
EP3753937A1 (en) 2020-12-23
DK3753937T3 (da) 2024-02-12
AU2019217388C1 (en) 2024-03-07
US11434232B2 (en) 2022-09-06
CN111712499B (zh) 2023-06-02
HRP20240161T1 (hr) 2024-04-12
US20200399260A1 (en) 2020-12-24
AU2019217388B2 (en) 2023-11-09
RU2020128324A3 (zh) 2022-03-09

Similar Documents

Publication Publication Date Title
CN111712499A (zh) 一种atr抑制剂及其应用
JP7352587B2 (ja) Ｋｒａｓｇ１２ｃ突然変異タンパク質阻害剤としてのピリドン－ピリミジン系誘導体
JP6877407B2 (ja) Ｎｔｒｋ関連障害の治療に有用な化合物および組成物
CN111372925B (zh) 作为c-MET/AXL抑制剂的尿嘧啶类化合物
WO2020048546A1 (zh) 三环取代哌啶二酮类化合物
JP2016537369A (ja) カゼインキナーゼ１ｄ／ｅ阻害剤としての置換された４，５，６，７−テトラヒドロピラゾロ［１，５−ａ］ピラジン誘導体
BR112021004269A2 (pt) composto de fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, uso do mesmo, relacionada à proteína crbn e método para tratamento da mesma
CN111683928B (zh) 作为fgfr抑制剂的吡嗪-2(1h)-酮类化合物
CN109867676A (zh) 一种吡咯并嘧啶衍生的化合物、药物组合物以及其用途
CN113321654A (zh) 作为激酶抑制剂的稠合吡啶酮类化合物
KR20200058483A (ko) 티에노디아제핀 유도체 및 그의 적용
CN113874379B (zh) 作为Cdc7抑制剂的四并环类化合物
RU2771201C2 (ru) ПИРИДОПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ, ВЫПОЛНЯЮЩИЕ ФУНКЦИЮ ДВОЙНЫХ ИНГИБИТОРОВ mTORC 1/2
JP6900406B2 (ja) Ａｋｔ阻害剤としてのジヒドロピラゾロアゼピン系化合物
WO2021197467A1 (zh) 多靶点的抗肿瘤化合物及其制备方法和应用
CN111971285B (zh) 咪唑并吡咯酮化合物及其应用
RU2799047C2 (ru) Ингибитор atr и его применение
CN114591319A (zh) 四氢吡啶并嘧啶类衍生物及其用途
TW201927777A (zh) Ido抑制劑

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40036987

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20220124

Address after: 214000 room 315, No. 88, Meishan Meiliang Road, Binhu District, Wuxi City, Jiangsu Province

Applicant after: Wuxi Zhikang Hongyi Biotechnology Co.,Ltd.

Address before: 050000 16th floor, innovation building, 315 Changjiang Avenue, hi tech Zone, Shijiazhuang, Hebei Province

Applicant before: Shijiazhuang Zhikang Hongren New Drug Development Co.,Ltd.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant